I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 74% ± 19% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 74% ± 19% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 43% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 56065.05 | 226 / 226 | 97% | 267.38 | 394 / 406 |
| adrenal gland | 100% | 312.53 | 257 / 258 | 67% | 2.61 | 153 / 230 |
| pancreas | 98% | 209.77 | 320 / 328 | 67% | 3.72 | 120 / 178 |
| thymus | 99% | 181.16 | 647 / 653 | 61% | 1.78 | 372 / 605 |
| kidney | 96% | 133.78 | 85 / 89 | 60% | 3.40 | 541 / 901 |
| brain | 96% | 234.09 | 2537 / 2642 | 19% | 0.38 | 134 / 705 |
| prostate | 91% | 105.98 | 224 / 245 | 10% | 0.16 | 49 / 502 |
| breast | 71% | 54.68 | 326 / 459 | 30% | 1.32 | 335 / 1118 |
| lung | 83% | 83.44 | 478 / 578 | 17% | 0.40 | 198 / 1155 |
| spleen | 98% | 191.94 | 236 / 241 | 0% | 0 | 0 / 0 |
| stomach | 77% | 748.43 | 278 / 359 | 15% | 0.32 | 42 / 286 |
| bladder | 43% | 35.43 | 9 / 21 | 21% | 0.71 | 107 / 504 |
| intestine | 49% | 68.86 | 469 / 966 | 7% | 1.10 | 38 / 527 |
| ovary | 17% | 10.15 | 31 / 180 | 34% | 0.82 | 148 / 430 |
| uterus | 36% | 33.68 | 62 / 170 | 14% | 0.34 | 64 / 459 |
| adipose | 45% | 32.41 | 543 / 1204 | 0% | 0 | 0 / 0 |
| esophagus | 13% | 8.93 | 184 / 1445 | 18% | 0.28 | 33 / 183 |
| blood vessel | 30% | 17.83 | 397 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 28% | 0.69 | 8 / 29 |
| muscle | 22% | 14.72 | 177 / 803 | 0% | 0 | 0 / 0 |
| skin | 13% | 8.04 | 243 / 1809 | 3% | 0.09 | 16 / 472 |
| peripheral blood | 16% | 35.28 | 150 / 929 | 0% | 0 | 0 / 0 |
| heart | 15% | 8.90 | 125 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.03 | 2 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 0.02 | 1 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0046456 | Biological process | icosanoid biosynthetic process |
| GO_0042573 | Biological process | retinoic acid metabolic process |
| GO_0097267 | Biological process | omega-hydroxylase P450 pathway |
| GO_0019373 | Biological process | epoxygenase P450 pathway |
| GO_0042178 | Biological process | xenobiotic catabolic process |
| GO_0006082 | Biological process | organic acid metabolic process |
| GO_0042572 | Biological process | retinol metabolic process |
| GO_0002933 | Biological process | lipid hydroxylation |
| GO_0008210 | Biological process | estrogen metabolic process |
| GO_0042759 | Biological process | long-chain fatty acid biosynthetic process |
| GO_0070989 | Biological process | oxidative demethylation |
| GO_0008202 | Biological process | steroid metabolic process |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0070330 | Molecular function | aromatase activity |
| GO_0016712 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen |
| GO_0101020 | Molecular function | estrogen 16-alpha-hydroxylase activity |
| GO_0004497 | Molecular function | monooxygenase activity |
| GO_0005506 | Molecular function | iron ion binding |
| GO_0008401 | Molecular function | retinoic acid 4-hydroxylase activity |
| GO_0020037 | Molecular function | heme binding |
| GO_0034875 | Molecular function | caffeine oxidase activity |
| GO_0008392 | Molecular function | arachidonic acid epoxygenase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CYP2C8 |
| Protein name | Cytochrome P450 family 2 subfamily C member 8 (Cytochrome P450, family 2, subfamily C, polypeptide 8, isoform CRA_b) Cytochrome P450 2C8 (EC 1.14.14.1) (CYPIIC8) (Cytochrome P450 IIC2) (Cytochrome P450 MP-12) (Cytochrome P450 MP-20) (Cytochrome P450 form 1) (S-mephenytoin 4-hydroxylase) Cytochrome P450 family 2 subfamily C member 8 (cDNA FLJ59467, highly similar to Cytochrome P450 2C8) Cytochrome P450 family 2 subfamily C member 8 |
| Synonyms | hCG_39487 |
| Description | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) . Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond . Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form . Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1) . Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol) . . |
| Accessions | ENST00000371270.6 [P10632-1] G3V188 E9PLI9 B7Z1F5 ENST00000527420.5 ENST00000628935.1 A0A0D9SG51 ENST00000623108.3 ENST00000525991.5 ENST00000535898.5 [P10632-2] P10632 ENST00000490994.6 E9PIW6 |
